Crescent Biopharma (CBIO) Cash from Operations (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Cash from Operations of 19463000.0 for Q2 2026, down 18.66% year-over-year from 23928650.48 in Q2 2025, and down 117.78% quarter-over-quarter from 8937000.0 in Q1 2026.
Crescent Biopharma (CBIO) Cash from Operations (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Cash from Operations for 14 consecutive years, with 19463000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 18.66% year-over-year to 19463000.0; the TTM figure through Jun 2026 stood at 72679000.0 (down 116.81% YoY), while the FY2025 annual figure was 71532000.0, down 130.01% from the prior year.
- Cash from Operations fell to 19463000.0 in Q2 2026 per CBIO's latest filing, from 8937000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 6269000.0 in Q4 2024 and bottomed at 26732000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 12172976.18 across 5 years, with a median of 10508829.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 57.03% — and 2025, when it plunged 326.42%.
- Crescent Biopharma's Cash from Operations stood at 7911569.0 in 2022, then increased by 3.75% to 7614997.0 in 2023, then advanced by 17.68% to 6269000.0 in 2024, then slumped by 326.42% to 26732000.0 in 2025, then advanced by 27.19% to 19463000.0 in 2026.
- Business Quant data shows CBIO's Cash from Operations at 19463000.0 in Q2 2026, 8937000.0 in Q1 2026, and 26732000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 728.46 Mn |
| 10 | Crescent Biopharma | 1.07 Bn | 901.41 Mn | - | -19.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.46 Mn |
| Jun 30, 2026 | -19.46 Mn |
| Mar 31, 2026 | -8.90 Mn |
| Mar 31, 2026 | -8.90 Mn |
| Dec 31, 2025 | -26.73 Mn |
| Dec 31, 2025 | -26.73 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Sep 30, 2025 | -17.50 Mn |
| Jun 30, 2025 | -16.45 Mn |
| Jun 30, 2025 | -16.45 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Mar 31, 2024 | -10.51 Mn |
| Mar 31, 2024 | -10.51 Mn |
| Dec 31, 2023 | -7.61 Mn |
| Dec 31, 2023 | -7.61 Mn |